Washington, D.C. 20549









Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 7, 2020





(Exact name of registrant as specified in its charter)


Delaware   000-53078   42-1743430

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


2 Burlington Woods Drive, Ste. 100

Burlington, MA

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (732) 661-2224




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
NA   NA   NA


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)


Emerging growth company [X]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]







Item 8.01 Other Events


On January 7, 2020, the Company issued a press release regarding the completion of preclinical study of the rhNELL-1 growth factor.


Item 9.01. Financial Statements and Exhibits.


  (d) Exhibits


There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.


Exhibit No.   Description
99.1   Press Release dated January 7, 2020 regarding the completion of preclinical study of the rhNELL-1 growth factor





Index to Exhibits


Exhibit No.   Description
99.1   Press Release dated January 7, 2020 regarding the completion of preclinical study of the rhNELL-1 growth factor







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 8, 2020 Bone Biologics Corporation
  Name: Jeffrey Frelick
  Title: Chief Executive Officer








Bone Biologics : Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation


01/07/2020 | 02:09pm EST


Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.


“The results of this Pivotal animal study provide a promising view of the potential of rhNELL-1 and we look forward to advancing the NELL spine program into clinical trials,” said Jeff Frelick, Chief Executive Officer of Bone Biologics.


“In its second clinically relevant sheep study, rhNELL-1 demonstrated increases in fusion and quantity of bone compared to the control,” said Dr. Bill Walsh, Professor and Director, Surgical and Orthopedic Research Laboratories (SORL), UNSW Sydney.


Bone Biologics previously announced that it received Human Research Ethics Committee (HREC) approval for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion (TLIF).


About Bone Biologics


Bone Biologics (OTCQB: BBLG) is pursuing regenerative medicine for bone including undertaking groundbreaking work and building on unprecedented research on the NELL-1 molecule that has produced a significant number of studies and publications in peer reviewed scientific literature.


Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. NELL-1 is a recombinant human protein growth factor that is essential for normal bone development.


View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005988/en/